Multivariate analysis on risk factors for TA-TMA
| Factors . | OR . | P . |
|---|---|---|
| >1 HSCT vs 1 HSCT | 5.1 | .002 |
| Active comorbidity vs none | 5.2 | .016 |
| aGVHD grade III to IV vs grade 0 to II | 26.9 | <.0001 |
| Use of haplo-HSCT vs other grafts | 1.1 | .21 |
| Use of calcineurin inhibitor vs none | 0.3 | .16 |
| Factors . | OR . | P . |
|---|---|---|
| >1 HSCT vs 1 HSCT | 5.1 | .002 |
| Active comorbidity vs none | 5.2 | .016 |
| aGVHD grade III to IV vs grade 0 to II | 26.9 | <.0001 |
| Use of haplo-HSCT vs other grafts | 1.1 | .21 |
| Use of calcineurin inhibitor vs none | 0.3 | .16 |